4D Path Announces Strategic Financing and Appointment of Katherine Vega Stultz and Robert J. Hombach to Its Board of Directors
Financing to accelerate 4D Path's pipeline of treatment predictive biomarkers in solid tumors. 4D Path adds two seasoned healthcare executives to strengthen its board and accelerate growth. Ms. Stultz to serve as 4D Path Board Chair
4D Path, a company dedicated to personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy, today announced the first close of a strategic financing round to accelerate the development of treatment predictive biomarkers for 4D Path-sponsored clinical use and partnerships with Biopharma companies.
4D Path's strategy is to develop digital treatment prediction biomarkers that inform more clear and accurate treatment selection earlier in the disease process. 4D Path has pan-cancer potential and is six for six in delivering clinically relevant results across breast, ovarian, colorectal, and skin cancers, across stages (e.g., early-stage and metastatic), with existing standards of care (chemotherapy, immunotherapy) and investigational therapies.
Katherine Vega Stultz and Robert "Bob" J. Hombach have been appointed to the Board of Directors to strengthen and diversify the organization as it enters a new stage of exciting, accelerated growth.
Ms. Stultz brings several decades of leadership in strategy, clinical development and commercialization, building high-performing teams and delivering therapies from bench to bedside across modalities and diseases including oncology. She has previously served in Board capacities in private and public companies. Ms. Stultz will serve as 4D Path's Board Chair.
Mr. Hombach is a highly accomplished financial and operational executive with three decades of leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of Directors, such as FORTUNE 500 companies like BioMarin (NASDAQ:BMRN), as well as Seaport Therapeutics.
"We are excited to add Katherine and Bob to our board. Katherine's deep expertise in oncology strategy, R&D, and commercialization coupled with Bob's company strategy, financial and operational expertise perfectly complement the outstanding group of leaders on our board," said Jacopo Leonardi, CEO of 4D Path. "Their addition coupled with our strategic financing will serve as a catalyst to bring this promising treatment predictive technology one step closer to helping patients around the world beat cancer."
Ms. Stultz has launched several multi-billion dollar products and directed the clinical project organization worldwide at Celgene overseeing over 30 mid/late stage clinical programs across hematology and oncology. Ms. Stultz is currently CEO and President of BrainXell Therapeutics Global Inc.
"I am thrilled to be a part of the 4D Path growth story as the company embarks on further generating clinical evidence and advancing partnerships to better identify the most appropriate treatment approach for an individual patient. This is a critical unmet need for medical oncologists and a development challenge as companies progress their clinical strategies."
Mr. Hombach served as the Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta (NYSE:BXLT), a $6 billion global biopharmaceutical company, until it was acquired by Shire plc. in 2016. He was instrumental in Baxalta's successful spin off from its parent company, Baxter (NYSE:BAX), a nearly $18 billion company, where he previously served as Corporate Vice President and Chief Financial Officer.
"I am very excited to join the Board of 4D Path as the company builds a compelling growth trajectory of tremendous potential benefit for patients, providers, drug developers, and investors."
About 4D Path
4D Path has created a groundbreaking platform, the patented Q-Plasia OncoReader (QPOR™), designed to directly measure and quantify cell cycle deregulation and tumor immune microenvironment dynamics to predict a patient's response to therapy. This unprecedented view into tumor dynamics creates new pathways from clinical use to research and development applications—bringing more effective, personalized therapies to patients. 4D Path is focused on a bold vision where every person impacted by cancer is diagnosed quickly and accurately and receives the best, most personalized treatment plan to beat cancer and live a longer, healthier life.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260505219674/en/
Media Contacts
4D Path Media Contact
4dpathpress@4dpath.com
(617) 558-0010